Nuvalent
NUVL
NUVL was delisted on the 14th of July, 2026.
154 hedge funds and large institutions have $4.7B invested in Nuvalent in 2023 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 73 increasing their positions, 25 reducing their positions, and 6 closing their positions.
650% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 6
369% more call options, than puts
Call options by funds: $85.5M | Put options by funds: $18.2M
192% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 25
83% more capital invested
Capital invested by funds: $2.57B → $4.7B (+$2.14B)
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
34% more funds holding
Funds holding: 115 → 154 (+39)
3.47% more ownership
Funds ownership: 108.24% → 111.72% (+3.5%)
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$137M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.4M |
| 4 |
CC
Commodore Capital
New York
|
+$31.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$28.1M |
Top Sellers
NUVL Hedge Fund Activity: Q4 2023 in Review
154 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Nuvalent (NUVL) for Q4 2023, worth a combined $4.7B — up 83% from $2.57B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new NUVL positions and 6 closed out — a net gain of 39 holders — while 73 added to existing stakes and 25 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $137M. The largest seller was Avoro Capital Advisors, cutting an estimated $39.2M.
- 154 institutional investors held Nuvalent (NUVL) as of Q4 2023, up from 115 in Q3 2023.
- Funds reported $4.7B of Nuvalent stock for Q4 2023, up 83% quarter-over-quarter.
- 45 funds opened new Nuvalent positions in Q4 2023 and 6 closed out, a net change of +39 holders.
- The largest Nuvalent buyer in Q4 2023 was Paradigm Biocapital Advisors, an estimated $137M added.
- The largest Nuvalent seller in Q4 2023 was Avoro Capital Advisors, an estimated $39.2M sold.
Based on aggregated 13F filings for Q4 2023.